TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been assigned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $11.79.

A number of analysts recently weighed in on TLSI shares. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Finally, Roth Mkm restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th.

Insider Transactions at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius acquired 62,972 shares of TriSalus Life Sciences stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mary T. Szela acquired 5,030 shares of TriSalus Life Sciences stock in a transaction that occurred on Wednesday, January 29th. The stock was bought at an average price of $5.03 per share, with a total value of $25,300.90. Following the purchase, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at approximately $2,209,422.47. This trade represents a 1.16 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 118,868 shares of company stock worth $541,943. Company insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the period. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $184,000. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $108,000. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $92,000. Finally, Walleye Capital LLC purchased a new position in TriSalus Life Sciences during the 3rd quarter valued at about $66,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $5.11 on Monday. The stock has a market cap of $155.80 million, a P/E ratio of -2.05 and a beta of 0.51. The firm has a fifty day moving average price of $4.60 and a 200 day moving average price of $4.75. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.